These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

419 related items for PubMed ID: 20107315

  • 41. Targeting histone deacetylases (HDACs) and Wee1 for treating high-risk neuroblastoma.
    Hanmod SS, Wang G, Edwards H, Buck SA, Ge Y, Taub JW, Wang Z.
    Pediatr Blood Cancer; 2015 Jan; 62(1):52-9. PubMed ID: 25308916
    [Abstract] [Full Text] [Related]

  • 42. Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo.
    Qi W, Zhang W, Edwards H, Chu R, Madlambayan GJ, Taub JW, Wang Z, Wang Y, Li C, Lin H, Ge Y.
    Cancer Biol Ther; 2015 Jan; 16(12):1784-93. PubMed ID: 26529495
    [Abstract] [Full Text] [Related]

  • 43. The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors.
    Parsels LA, Parsels JD, Tanska DM, Maybaum J, Lawrence TS, Morgan MA.
    Cell Cycle; 2018 Jan; 17(9):1076-1086. PubMed ID: 29895190
    [Abstract] [Full Text] [Related]

  • 44. Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma.
    Lescarbeau RS, Lei L, Bakken KK, Sims PA, Sarkaria JN, Canoll P, White FM.
    Mol Cancer Ther; 2016 Jun; 15(6):1332-43. PubMed ID: 27196784
    [Abstract] [Full Text] [Related]

  • 45. Administration sequence-dependent antitumor effects of paclitaxel and 5-fluorouracil in the human gastric cancer cell line MKN45.
    Toiyama Y, Tanaka K, Konishi N, Mohri Y, Tonouchi H, Miki C, Kusunoki M.
    Cancer Chemother Pharmacol; 2006 Feb; 57(3):368-75. PubMed ID: 16075279
    [Abstract] [Full Text] [Related]

  • 46. The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma.
    Pokorny JL, Calligaris D, Gupta SK, Iyekegbe DO, Mueller D, Bakken KK, Carlson BL, Schroeder MA, Evans DL, Lou Z, Decker PA, Eckel-Passow JE, Pucci V, Ma B, Shumway SD, Elmquist WF, Agar NY, Sarkaria JN.
    Clin Cancer Res; 2015 Apr 15; 21(8):1916-24. PubMed ID: 25609063
    [Abstract] [Full Text] [Related]

  • 47. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.
    Montano R, Chung I, Garner KM, Parry D, Eastman A.
    Mol Cancer Ther; 2012 Feb 15; 11(2):427-38. PubMed ID: 22203733
    [Abstract] [Full Text] [Related]

  • 48. Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells.
    Isono M, Okubo K, Asano T, Sato A.
    Sci Rep; 2021 May 13; 11(1):10181. PubMed ID: 33986399
    [Abstract] [Full Text] [Related]

  • 49. Development of Potent Pyrazolopyrimidinone-Based WEE1 Inhibitors with Limited Single-Agent Cytotoxicity for Cancer Therapy.
    Matheson CJ, Casalvieri KA, Backos DS, Reigan P.
    ChemMedChem; 2018 Aug 20; 13(16):1681-1694. PubMed ID: 29883531
    [Abstract] [Full Text] [Related]

  • 50. Chk1 and Wee1 control genotoxic-stress induced G2-M arrest in melanoma cells.
    Vera J, Raatz Y, Wolkenhauer O, Kottek T, Bhattacharya A, Simon JC, Kunz M.
    Cell Signal; 2015 May 20; 27(5):951-60. PubMed ID: 25683911
    [Abstract] [Full Text] [Related]

  • 51. WEE1 kinase inhibition enhances the radiation response of diffuse intrinsic pontine gliomas.
    Caretti V, Hiddingh L, Lagerweij T, Schellen P, Koken PW, Hulleman E, van Vuurden DG, Vandertop WP, Kaspers GJ, Noske DP, Wurdinger T.
    Mol Cancer Ther; 2013 Feb 20; 12(2):141-50. PubMed ID: 23270927
    [Abstract] [Full Text] [Related]

  • 52. Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress.
    Cuneo KC, Morgan MA, Davis MA, Parcels LA, Parcels J, Karnak D, Ryan C, Liu N, Maybaum J, Lawrence TS.
    Int J Radiat Oncol Biol Phys; 2016 Jun 01; 95(2):782-90. PubMed ID: 26975930
    [Abstract] [Full Text] [Related]

  • 53. Differences in the induction of DNA damage, cell cycle arrest, and cell death by 5-fluorouracil and antifolates.
    Backus HH, Pinedo HM, Wouters D, Kuiper CM, Jansen G, van Groeningen CJ, Peters GJ.
    Oncol Res; 2000 Jun 01; 12(5):231-9. PubMed ID: 11417748
    [Abstract] [Full Text] [Related]

  • 54. Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation.
    Pfister SX, Markkanen E, Jiang Y, Sarkar S, Woodcock M, Orlando G, Mavrommati I, Pai CC, Zalmas LP, Drobnitzky N, Dianov GL, Verrill C, Macaulay VM, Ying S, La Thangue NB, D'Angiolella V, Ryan AJ, Humphrey TC.
    Cancer Cell; 2015 Nov 09; 28(5):557-568. PubMed ID: 26602815
    [Abstract] [Full Text] [Related]

  • 55. Chloroquine enhances the chemotherapeutic activity of 5-fluorouracil in a colon cancer cell line via cell cycle alteration.
    Choi JH, Yoon JS, Won YW, Park BB, Lee YY.
    APMIS; 2012 Jul 09; 120(7):597-604. PubMed ID: 22716215
    [Abstract] [Full Text] [Related]

  • 56. Pseudolaric acid B induces mitotic arrest and apoptosis in both 5-fluorouracil-sensitive and -resistant colorectal cancer cells.
    Wen C, Chen J, Zhang D, Wang H, Che J, Qin Q, He L, Cai Z, Lin M, Lou Q, Huang L, Chen D, Iwamoto A, Ren D, Wang L, Lan P, Wang J, Liu H, Yang X.
    Cancer Lett; 2016 Dec 28; 383(2):295-308. PubMed ID: 27713084
    [Abstract] [Full Text] [Related]

  • 57. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe.
    De Witt Hamer PC, Mir SE, Noske D, Van Noorden CJ, Würdinger T.
    Clin Cancer Res; 2011 Jul 01; 17(13):4200-7. PubMed ID: 21562035
    [Abstract] [Full Text] [Related]

  • 58. WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.
    Richer AL, Cala JM, O'Brien K, Carson VM, Inge LJ, Whitsett TG.
    Cancer Res; 2017 Sep 01; 77(17):4663-4672. PubMed ID: 28652249
    [Abstract] [Full Text] [Related]

  • 59. Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition.
    Meng F, Bhupathi D, Sun JD, Liu Q, Ahluwalia D, Wang Y, Matteucci MD, Hart CP.
    BMC Cancer; 2015 May 21; 15():422. PubMed ID: 25994202
    [Abstract] [Full Text] [Related]

  • 60. Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth.
    Golubovskaya VM, Ho B, Zheng M, Magis A, Ostrov D, Morrison C, Cance WG.
    BMC Cancer; 2013 Jul 11; 13():342. PubMed ID: 23841915
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.